Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shubutinib
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Shubutinib is an orally bioavailable, multi-target small molecule tyrosine kinase inhibitor (TKI) developed by Jiangsu Chia Tai Tianqing Pharmaceutical. It primarily targets vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), platelet-derived growth factor receptors (PDGFR-alpha and -beta), and the mast/stem cell growth factor receptor (c-Kit). By inhibiting these receptor tyrosine kinases, shubutinib disrupts key signaling pathways involved in tumor angiogenesis and direct tumor cell proliferation. It has been investigated in Phase 1 clinical trials for the treatment of advanced malignant solid tumors in patients who have failed standard therapies. The compound is often described as a derivative or analog of sunitinib with optimized pharmacological properties.
- Other names
- shubutinib malate舒布替尼
02
Targets
BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on shubutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shubutinib.